LENSAR, Inc.

NASDAQ:LNSR

Medical - Devices

Healthcare
$4.85 -8.15%

-$0.51 today

Market cap
$59.63M
Beta
0.87
P/E (TTM)
2.4
EPS (TTM)
$2.42
52W Low $5.06High $13.47

Volume 0.06M

Average 0.09M

LNSR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

LENSAR, Inc.NASDAQ: LNSR

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 47.5%

Gross margin was 47.5% in Q1 FY2026, down 2.8 pp from a year earlier. On a trailing-twelve-month basis it was 45.3%, down 2.1 pp year over year. Over 3 fiscal years it narrowed by 10.0 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
47.5%+4.2 pp QoQ
Last fiscal yearDec 2025
46.4%-1.9 pp YoY
LTMMar 2026
45.3%-2.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.8 pp——
1 year-1.9 pp——
3 years-10.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
46.4%
Year-over-year change
-1.9pp

Gross Margin vs competitors

How LNSR compares with its peers on the latest reported figures

  • LNSR's LTM Mar 2026 gross margin of 45.3% is the 6th highest of the 9 companies compared; the peer median is 54.7%.
  • Its year-over-year change of -2.1 pp is the 6th highest of 9, against a peer median of -1.0 pp.
  • Over three fiscal years its change of -10.0 pp compares with a peer median of +1.4 pp.
LNSR Competitors Peer median
Gross Margin for LNSR and competitors
Company Period LTM level YoY 3-year change
TLSITriSalus Life Sciences, Inc.LTM Mar 202685.1% -0.5 pp+2.8 pp
MXCTMaxCyte, Inc.LTM Mar 202680.7% -0.2 pp-7.3 pp
PROFProfound Medical Corp.LTM Mar 202671.1% +4.4 pp+25.6 pp
ANIKAnika Therapeutics, Inc.LTM Mar 202658.6% -4.1 pp-7.8 pp
OWLTOwlet, Inc.LTM Mar 202650.9% -1.4 pp+17.0 pp
LNSRLENSAR, Inc.LTM Mar 202645.3% -2.1 pp-10.0 pp
AVRAnteris Technologies Global Corp.LTM Mar 202628.3% -24.8 pp-25.9 pp
RPIDRapid Micro Biosystems, Inc.LTM Mar 202612.4% +6.3 pp+72.5 pp
CRDFCardiff Oncology, Inc.LTM Mar 2026-2105.7% -548.4 pp+0.0 pp
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
Peer median (excluding LNSR) 54.7%-1.0 pp+1.4 pp

Competitors are the stored peer set for LNSR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.46M35.36M42.16M53.49M58.44M
Cost of Revenue16.63M15.4M21.06M27.64M31.31M
Gross Profit17.83M19.96M21.11M25.85M27.12M
Gross Margin51.8%56.4%50.1%48.3%46.4%
Research & Development12.36M11.81M6.14M5.33M5.62M
Selling, General & Admin23.89M27.17M26.1M26.49M45.16M
Operating Expenses37.49M40.13M33.34M36.52M51.7M
Depreciation & Amortization2.76M3.41M3.52M3.93M4.5M
EBITDA(16.84M)(16.51M)(10.87M)(3.01M)(29.78M)
EBITDA Margin-48.9%-46.7%-25.8%-5.6%-51.0%
Operating Income(19.65M)(20.18M)(12.23M)(10.67M)(24.58M)
Operating Margin-57.0%-57.1%-29.0%-19.9%-42.1%
Interest Income34K17K85K103K91K
Interest Expense00000
Other Income / Expenses51K263K(2.15M)(20.74M)(9.7M)
Income Before Tax(19.6M)(19.91M)(14.38M)(31.4M)(34.28M)
Pre-Tax Margin-56.9%-56.3%-34.1%-58.7%-58.7%
Income Tax Expense00000
Net Income(19.6M)(19.91M)(14.38M)(31.4M)(34.28M)
Net Margin-56.9%-56.3%-34.1%-58.7%-58.7%
EPS (Basic)(2.10)(1.96)(1.31)(2.73)(2.87)
EPS (Diluted)(2.10)(1.96)(1.31)(2.73)(2.87)
Weighted Avg Shares9.37M10.16M10.97M11.52M11.96M
Weighted Avg Shares (Diluted)9.37M10.16M10.97M11.52M11.96M

LENSAR, Inc.

NASDAQ:LNSR

Intrinsic Alpha fair value

Locked

Current Price

$4.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.